Please assess the completion status of the following clinical trial:

Trial Title: Ramipril in Pediatric Patients on Hemodialysis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2/PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients \< 16 years old~* Patients who have been on regular HD for 6 months or longer~* Hypertension at enrollment~Exclusion Criteria:~* History of active connective tissue disease~* Acute infection within 1 month prior to the study~* Advanced liver disease~* Gastrointestinal dysfunction requiring parental nutrition or active malignancy~* Use of medications such as immunosuppressive drugs within 1 month prior to the study~* Use of anti-inflammatory medications~* Use of vitamin E at a dose higher than 60 IU per day or vitamin C higher than 500 mg per day~* History of myocardial infarction or cerebrovascular event within 3 months prior to the study~* History of ACE inhibitor-associated angioedema~* Inability to discontinue ACE inhibitors or ARBs

- Gender: ALL
- Minimum Age: 8 Years
- Maximum Age: 16 Years
- Healthy Volunteers: f

Study Arms:
- Ramipril (Type: EXPERIMENTAL): Ramipril, 2.5 mg daily, administered orally for 16 weeks
- Placebo (Type: PLACEBO_COMPARATOR): Placebo, matched for the interventional drug, administered orally, daily for 16 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).